$ARMP
Armata Pharmaceuticals, Inc.
NYSE · Healthcare · Biological Products, (No Diagnostic Substances) · Los Angeles, CA
ARMP chart
What traders are saying about $ARMP
Latest postsArmata Pharmaceuticals, Inc. news
- Armata Pharmaceuticals, Inc. Estimates – AMEX:ARMP
TradingView ·
- Cystic Fibrosis Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape
StreetInsider ·
- Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States
Yahoo Finance ·
- Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development
Yahoo Finance ·
- Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates
Yahoo Finance ·
- Armata Pharmaceuticals Shares Rise 8% After FDA Grants AP-SA02 Breakthrough Therapy Designation
investorshub.advfn.com ·
- Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02
Yahoo Finance ·
- Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Yahoo Finance ·
- Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials
Yahoo Finance ·
- Bronchiectasis Market is Expected to Surge at a CAGR of 15% by 2036, Owing to the Launch of DPP1/CatC Inhibitors, Therapeutic Phage Cocktails, Nebulized Mucoactive Agents, and Other Novel Mechanisms | DelveInsight
Yahoo Finance ·
- Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update
Yahoo Finance ·
- Armata Pharmaceuticals (ARMP) Stock Jumps 12.2%: Will It Continue to Soar?
Yahoo Finance ·
Armata Pharmaceuticals, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$173.8M | -$18.9M | -$69.0M | -$36.9M |
| Diluted EPS | $-4.80 | $-0.89 | $-1.91 | $-1.08 |
| Total assets (year end) | $76.9M | $86.4M | $98.4M | $95.8M |
| Cash and equivalents (year end) | $8.7M | $9.3M | $13.5M | $14.9M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Armata Pharmaceuticals, Inc.
- Ticker
- ARMP (NYSE)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Los Angeles, CA
- Incorporated in
- WA
- Fiscal year end
- December 31
- SEC CIK
- 921114
- Former names
- AmpliPhi Biosciences Corp, TARGETED GENETICS CORP /WA/
Frequently asked questions
What exchange is Armata Pharmaceuticals, Inc. listed on?
Armata Pharmaceuticals, Inc. trades on the NYSE under the ticker symbol ARMP.
What industry is Armata Pharmaceuticals, Inc. in?
Armata Pharmaceuticals, Inc. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is Armata Pharmaceuticals, Inc. headquartered?
Armata Pharmaceuticals, Inc.'s business address on file with the SEC is in Los Angeles, CA.
When does Armata Pharmaceuticals, Inc.'s fiscal year end?
Armata Pharmaceuticals, Inc.'s fiscal year ends on December 31.